Organovo has patented a method using a three-dimensional bioprinted renal tubule model to assess therapeutic agents’ ability to reverse renal injury. The model mimics renal disorders like fibrosis induced by toxins or environmental agents. The model comprises renal interstitial and epithelial tissues, providing a platform for drug testing. GlobalData’s report on Organovo gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to GlobalData’s company profile on Organovo, 3D Bioprinting was a key innovation area identified from patents. Organovo's grant share as of May 2024 was 34%. Grant share is based on the ratio of number of grants to total number of patents.
Bioprinted model for assessing renal injury and function
A recently granted patent (Publication Number: US11982668B2) discloses a novel model of a renal disorder, featuring a three-dimensional, engineered, bioprinted, biological renal tubule model. This model comprises a layer of renal interstitial tissue containing renal fibroblasts and endothelial cells, along with a layer of renal epithelial tissue consisting of renal tubular epithelial cells. The model exhibits a phenotype characteristic of a renal disorder induced by various agents like toxins, antimicrobial agents, or metals. The ratio of fibroblasts to endothelial cells in the renal tubule model is crucial for maintaining its planar structure post-printing.
Furthermore, the patent claims describe additional features of the renal tubule model, such as the polarization of renal tubular epithelial cells, the presence of a basement membrane between the interstitial and epithelial tissue layers, and the composition of living cells in the tissue layers. The model can also include a biocompatible membrane, be multi-layered, and configured in arrays within microtiter plates. The induced phenotype in the model can manifest in various ways, including changes in cell morphology, alterations in gene expression, secretion of biomarkers, and even the death of surrounding tissue. This innovative model provides a valuable tool for studying renal disorders and potential treatments in a controlled laboratory setting.
To know more about GlobalData’s detailed insights on Organovo, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
